Online inquiry

IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11080MR)

This product GTTS-WQ11080MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF1 gene. The antibody can be applied in Pigmented villonodular synovitis (PVNS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000757.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1435
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11080MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11777MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ10441MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ11115MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ6614MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ11075MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ5801MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ8566MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ10583MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3127804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW